India-based Glenmark Pharmaceuticals is planning to introduce a phase one trial in solid tumours for its CD38xCD3 bispecific antibody, GBR 1342.

It was reported yesterday that the company has taken this decision based on recent findings derived from a non-interventional human study using a clinically validated CANscript platform. The product is based on the company's proprietary BEAT platform and simultaneously targets CD38, an antigen known to be implicated in haematological malignancies as well as some solid tumours, and the CD3 T cell co-receptor.

Glenmark Pharmaceuticals president and chief scientific officer Kurt Stoeckli said, 'Our work with innovative immunotherapeutics such as T cell re-directing bispecific antibodies necessitates detailed analyses to fully-understand and assess the potential opportunities presented by the candidates in our pipeline. We are pleased to report that predictive analytics have generated new insights on response rates which inform further clinical development of GBR 1342 in a variety of solid tumour types, both as monotherapy and in combination therapy.'

Glenmark intends to file an Investigational New Drug (IND) application for GBR 1342 in solid tumours and initiate a clinical trial in 2019.